Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
First Claim
1. A method of treating psychosis, or a symptom thereof, comprising administering to a patient suffering from psychosis, or a symptom thereof, a therapeutically effective amount of a compound of formula (I):
2 Assignments
0 Petitions
Accused Products
Abstract
Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that 5HT2A/2C receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson'"'"'s Disease, related human neurodegenerative diseases, and psychosis.
86 Citations
15 Claims
- 1. A method of treating psychosis, or a symptom thereof, comprising administering to a patient suffering from psychosis, or a symptom thereof, a therapeutically effective amount of a compound of formula (I):
Specification